Fortrea Holdings (FTRE) Operating Leases (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Operating Leases came in at $54.3 million in Q2 2026, up 2.65% YoY from $52.9 million in Q2 2025, and down 2.51% on a QoQ basis from $55.7 million in Q1 2026.
Fortrea Holdings (FTRE) Operating Leases (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Operating Leases data on file, last reported at $54.3 million in Q2 2026.
- Quarterly Operating Leases rose 2.65% year-over-year to $54.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.3 million (up 2.65% YoY) and the FY2025 annual result came in at $54.0 million, down 27.03% from the prior year.
- Operating Leases retreated to $54.3 million in Q2 2026, from $55.7 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $80.0 million in Q4 2023 to a low of $51.5 million in Q3 2025.
- A 5-year average of $61.2 million and a median of $59.3 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases climbed 26.18% — and 2025, when it retreated 27.03%.
- Tracing FTRE's Operating Leases over 5 years: stood at $63.4 million in 2022, then grew by 26.18% to $80.0 million in 2023, then declined by 7.5% to $74.0 million in 2024, then dropped by 27.03% to $54.0 million in 2025, then grew by 0.56% to $54.3 million in 2026.
- The last three Operating Leases figures came in at $54.3 million (Q2 2026), $55.7 million (Q1 2026), and $54.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.30 Mn |
| Mar 31, 2026 | 55.70 Mn |
| Dec 31, 2025 | 54.00 Mn |
| Sep 30, 2025 | 51.50 Mn |
| Jun 30, 2025 | 52.90 Mn |
| Mar 31, 2025 | 59.10 Mn |
| Dec 31, 2024 | 74.00 Mn |
| Sep 30, 2024 | 65.40 Mn |
| Jun 30, 2024 | 65.80 Mn |
| Mar 31, 2024 | 59.50 Mn |
| Dec 31, 2023 | 80.00 Mn |
| Sep 30, 2023 | 68.00 Mn |
| Jun 30, 2023 | 52.90 Mn |
| Dec 31, 2022 | 63.40 Mn |